 The study purpose is to determine the safety and efficacy of a belatacept-based immunosuppressive regimen calcineurin inhibitor free with alemtuzumab or rabbit antithymocyte globulin induction and early glucocorticoid withdrawal CSWD and a belatacept-based immunosuppressive regimen with tacrolimus-based regimen with rabbit antithymocyte globulin induction and early glucocorticoid withdrawal in renal transplant recipients. 